$1.12
+0.00 (+0.00%)
USD · as of 2026-08-20 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where LSTA is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
16 interventional · 1 observational · 6 with posted results
Held by 2 tracked-famous managers (JANE STREET GROUP, LLC, CITADEL ADVISORS LLC) · FINRA short interest 1.0 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Certepetide Phase 1b/2a Continuous Infusion Trial in mPDACNCT06592664Incidence of adverse eventsRandomized · Triple-masked · Treatment | Phase 1/2 | Withdrawnsponsor's stated reason: Management Decision | Drug: certepetide, nab-paclitaxel, gemcitabine, placebo matching certepetide, certepetide, placebo matching certepetide, placebo matching certepetide | Pancreas Cancer, Pancreatic Carcinoma, Pancreas Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Unresectable Pancreatic Cancer, Metastatic Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma | 0 | Jan 2035 | ≤ 3,085 d | 2025-06-06 |
| A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid TumorsNCT05712356results2026-05-26Number of Subjects Experiencing Any Adverse EventRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: The study was halted prematurely to allow analysis of the results. | Drug: certepetide, Durvalumab, Cisplatin, Gemcitabine, FOLFOX regimen, Placebo | Cholangiocarcinoma, Gallbladder Cancer, Gallbladder Carcinoma, Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma, Bile Duct Cancer, Gall Bladder Cancer, Gall Bladder Carcinoma | 66 | 2026-04-05actual | — | 2026-05-26 |
| CLBS201 in Patients with Chronic Kidney Disease (CKD) and Type 2 Diabetes Mellitus (T2DM)NCT04990427Serious Adverse EventsOpen-label · Treatment | Phase 1 | Completed | Drug: CLBS201 | Chronic Kidney Diseases | 6 | 2023-01-26actual | — | 2024-10-09 |
| A Placebo-Controlled Trial of CLBS16 in Subjects With Coronary Microvascular DysfunctionNCT04614467results2026-05-04Change From Baseline in Number of Angina Attacks Per WeekRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Sponsor decision | Biological: CLBS16, Placebo | Coronary Microvascular Dysfunction, Coronary Microvascular Disease, Microvascular Coronary Artery Disease | 34 | 2022-09-28actual | — | 2026-05-04 |
| Study to Assess the Efficacy and Safety of CLBS12 in Patients with Critical Limb Ischemia (CLI)NCT02501018Time to continuous CLI-free statusRandomized · Open-label · Treatment | Phase 2 | Completed | Biological: CLBS12 · Drug: SOC | Critical Limb Ischemia, Buerger Disease, Thromboangiitis Obliterans, Atherosclerosis Obliterans | 33 | 2022-05-19actual | — | 2024-10-09 |
| CLBS119 for Repair of COVID-19 Induced Pulmonary DamageNCT04522817Adverse eventsOpen-label · Treatment | Phase 1 | Withdrawnsponsor's stated reason: Acute COVID-19 treatments have improved significantly leading to decreased use of ventilatory support. This, coupled with approval of a vaccine, has changed the profile/prognosis of patients and led to a lack of patients with long-term hypoxia. | Biological: CLBS119 | Covid-19 | 0 | May 2021 | — | 2024-10-09 |
| CEND-1 in Combination With Nabpaclitaxel and Gemcitabine in Metastatic Pancreatic CancerNCT03517176Safe doses of CEND-1 when given alone or in combination with nabpaclitaxel and gemcitabineNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: CEND-1, Nab-paclitaxel, Gemcitabine | Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma | 30 | 2020-06-19actual | — | 2024-08-28 |
| Safety and Potential Bioactivity of CLBS16 in Patients With Coronary Microvascular Dysfunction and Without Obstructive Coronary Artery DiseaseNCT03508609results2021-01-08Change From Baseline in Coronary Flow ReserveOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Biological: CLBS16 | Coronary Microvascular Dysfunction | 20 | 2019-12-10actual | — | 2021-01-08 |
| Safety and Efficacy of CLBS03 in Adolescents With Recent Onset Type 1 Diabetes (The Sanford Project T-Rex Study)NCT02691247results2021-01-08Change From Baseline in 4-hour Mixed Meal Tolerance Test (MMTT)-Stimulated C-peptide Area Under the Curve (AUC) at Week 52Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Biological: CLBS03 Low Dose, CLBS03 High Dose, Placebo | Diabetes Mellitus | 113 | Mar 2019actual | — | 2021-01-08 |
| Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic MelanomaNCT01875653Overall survivalRandomized · Quadruple-masked · Treatment | Phase 3 | Terminated | Biological: Autologous Dendritic Cell-Tumor Cell Immunotherapy (DC-TC), Autologous PBMCs in GM-CSF (MC) | Stage IV Melanoma, Stage III Melanoma | 4 | Jan 2016actual | — | 2019-05-10 |
| Efficacy and Safety of Targeted Intramyocardial Delivery of Auto CD34+ Stem Cells for Improving Exercise Capacity in Subjects With Refractory AnginaNCT01508910results2017-02-15Change From Baseline in Total Exercise Time on Exercise Tolerance Test (ETT) Using the Modified Bruce ProtocolRandomized · Double-masked · Treatment | Phase 3 | Completed | Biological: Auto-CD34+ cells, Placebo: Diluent used to suspend Auto-CD34+ cells · Other: Standard of care | Chronic Myocardial Ischemia, Refractory Angina Pectoris, Advanced Coronary Heart Disease | 291 | Nov 2015actual | — | 2018-12-19 |
| NBS10 (Also Known as AMR-001) Versus Placebo Post ST Segment Elevation Myocardial InfarctionNCT01495364To determine safety and efficacy of intracoronary infusion of NBS10.Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Biological: NBS10 · Other: placebo | ST Segment Elevation Myocardial Infarction | 195 | Jun 2014actual | — | 2016-04-28 |
| Vaccine Therapy in Treating Patients With Stage IV or Recurrent MelanomaNCT00012064To determine the safety of administration of irradiated autologous tumor cells that have been incubated in vitro with gamma interferon, and subsequently injected subcutaneously with autologous dendritic cells and GMCSFNon-randomized · Open-label · Treatment | Phase 1/2 | Completed | Biological: therapeutic autologous dendritic cells | Melanoma (Skin) | 56 | Apr 2011actual | — | 2014-01-29 |
| Lymphokine-Activated Killer Cells or Gliadel Wafer in Treating Patients With Newly Diagnosed Glioblastoma Multiforme That Can Be Removed by SurgeryNCT00814593Overall survivalRandomized · Open-label · Treatment | Phase 2 | Withdrawnsponsor's stated reason: Hoag Hospital ceased support. | Biological: lymphokine-activated killer cells · Drug: polifeprosan 20 with carmustine implant | Brain and Central Nervous System Tumors | 0 | Apr 2011actual | — | 2019-05-10 |
| ACT34-CMI -- Adult Autologous CD34+ Stem Cells (Follow-Up Study)NCT00545610observationalLong-term safety of intramyocardial injections of Auto-CD34+ cells relative to placebo for reducing the number of angina episodes in subjects with refractory chronic myocardial ischemia over a 12-month follow-up period. | — | Completed | — | Myocardial Ischemia | 150 | Apr 2010actual | — | 2018-11-28 |
| Vaccine Therapy in Treating Patients With Kidney CancerNCT00014131Conversion of the delayed-type hypersensitivity (DTH) skin test as measured by metric skin ruler at week 4 and month 6 during vaccine therapyOpen-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: change in corporate priorities | Biological: Biological/Vaccine: therapeutic autologous dendritic cells. | Kidney Cancer | 9 | Dec 2009actual | — | 2023-10-04 |
| ACT34-CMI -- Adult Autologous CD34+ CellsNCT00300053results2021-01-08Number of Angina Episodes Per Week at 6 and 12 MonthsRandomized · Triple-masked · Treatment | Phase 2 | Completed | Biological: CLBS14 (low-dose), CLBS14 (high-dose), placebo injection | Myocardial Ischemia | 321 | Mar 2008actual | — | 2021-01-26 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19